FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine, in particular to ophthalmology. An agent is applicable for a cross-linking procedure accompanying corneal ectasias. The agent contains riboflavin mononucleotide, chitosan succinate, sodium chloride, tris-(hydroxymethyl)-methylamine, Nipagin, disodium dihydrogen ethylenediaminetetraacetate and purified distilled water in certain proportions.
EFFECT: invention provides prolonged action of the agent, improves bacteriological availability for active ingredients, reduces the length and number of instillations for the procedure, provides agent saving.
1 ex
| Title | Year | Author | Number | 
|---|---|---|---|
| HYPOSMOTIC OPHTHALMIC MEANS FOR ULTRAVIOLET CROSSLINKING OF THIN CORNEAS | 2016 | 
 | RU2631604C1 | 
| OPHTHALMOLOGICAL MEANS FOR ULTRAVIOLET CORNEAL CROSSLINKING | 2016 | 
 | RU2646452C1 | 
| CROSS-LINKING OPHTHALMIC AGENT | 2009 | 
 | RU2412707C1 | 
| OPHTHALMIC AGENT FOR TRANSEPITHELIAL ULTRAVIOLET CORNEAL COLLAGEN CROSSLINKING | 2014 | 
 | RU2560669C1 | 
| HYPO-OSMOTIC OPHTHALMIC AGENT FOR ULTRAVIOLET CROSS-LINKING OF THIN CORNEAS | 2024 | 
 | RU2841327C1 | 
| METHOD OF TREATING HERPETIC KERATITIS | 2013 | 
 | RU2531426C1 | 
| METHOD OF TREATMENT OF KERATECTASIA BY THE METHOD OF PULSE ACCELERATED ULTRAVIOLET CROSSLINKING OF CORNEA | 2017 | 
 | RU2682494C1 | 
| METHOD OF CORNEAL GRAFT PREPARATION FOR LAYER-BY-LAYER KERATOPLASTY | 2019 | 
 | RU2723135C1 | 
| COMBINED METHOD FOR THE TREATMENT OF CORNEAL DISEASES WITH THE USE OF KERATOPLASTY AND CROSS-LINKING | 2017 | 
 | RU2676434C1 | 
| METHOD OF TREATING EPITHELIAL-ENDOTHELIAL CORNEAL DYSTROPHY | 2019 | 
 | RU2703361C1 | 
Authors
Dates
2013-02-20—Published
2012-03-12—Filed